Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 201–300 of 1,052
Allara, E., Morani, G., Carter, P., Gkatzionis, A., Zuber, V., Foley, C. N., Rees, J. M. B., Mason, A. M., Bell, S., Gill, D., et al. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.119.002711 · Cited by 145
Mechanisms and Treatment of Dyslipidemia in Diabetes
Bahiru, E. M., Hsiao, R., Philipson, D. J., & Watson, K. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01455-w · Cited by 183
Role of coronary artery calcium score in the primary prevention of cardiovascular disease
Nasir, K., & Cainzos‐Achirica, M. (2021) · BMJ · doi:10.1136/bmj.n776 · Cited by 169
Thai, P. V., Tien, H. A., Minh, H. V., & Valensi, P. E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01108-2 · Cited by 152
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Van Dael, P. (2021) · Nutrition Research and Practice · doi:10.4162/nrp.2021.15.2.137 · Cited by 138
“The suggested use of n-3 LCPUFA (4 g/day) for improving atherosclerotic CVD risk in patients with hypertriglyceridemia is supported by the detection of a 25% reduction in major adverse cardiovascular events in the REDUCE-IT data.”
BackgroundMethodInfluentialAverna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 137
Cho, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073967 · Cited by 168
Small rodent models of atherosclerosis
Zhao, Y., Qu, H., Wang, Y., Xiao, W., Zhang, Y., & Shi, D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110426 · Cited by 158
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136
Self-citationFamilial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
Watts, G. F., Gidding, S. S., Mata, P., Pang, J., SULLIVAN, D. R., Yamashita, S., Raal, F. J., Santos, R. D., & Ray, K. K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0325-8 · Cited by 153
Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations
Newman, J. D., Bhatt, D. L., Rajagopalan, S., Balmes, J. R., Brauer, M. D., Breysse, P. N., Brown, A. G. M., Carnethon, M. R., Cascio, W. E., Collman, G. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.020 · Cited by 139
Self-citationArellanes, I. C., Choe, N., Solomon, V., He, X., Kavin, B., Martinez, A. E., Kono, N., Buennagel, D. P., Hazra, N., Kim, G., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102883 · Cited by 134
Albert, C. M., Cook, N. R., Pester, J., Moorthy, M. V., Ridge, C., Danik, J. S., Gencer, B., Siddiqi, H. K., Ng, C., Gibson, H., et al. (2021) · JAMA · doi:10.1001/jama.2021.1489 · Cited by 133
Ten things to know about ten cardiovascular disease risk factors – 2022
Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 171
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01075-x · Cited by 129
Self-citationRidker, P. M., Rifai, N., MacFadyen, J., Glynn, R. J., Jiao, L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059410 · Cited by 131
Self-citationWatanabe, Y., & Tatsuno, I. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.50658 · Cited by 156
Preston Mason, R. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0762-1 · Cited by 129
Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment
Lordan, R., Rando, H. M., & Greene, C. S. (2021) · mSystems · doi:10.1128/msystems.00122-21 · Cited by 145
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 205
Nakano, S., Kohsaka, S., Chikamori, T., Fukushima, K., Kobayashi, Y., Kozuma, K., Manabe, S., Matsuo, H., Nakamura, M., Ohno, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1041 · Cited by 146
So, J., Wu, D., Lichtenstein, A. H., Tai, A. K., Matthan, N. R., Maddipati, K. R., & Lamon-Fava, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.018 · Cited by 127
Sajja, A., Park, J., Sathiyakumar, V., Varghese, B., Pallazola, V. A., Marvel, F. A., Kulkarni, K., Muthukumar, A., Joshi, P. H., Gianos, E., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28817 · Cited by 127
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s005 · Cited by 265
Qu, L., Fang, S., Lan, Z., Xu, S., Jiang, J., Pan, Y., Xu, Y., Zhu, X., & Jin, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02314-y · Cited by 136
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
Vijay, A., Astbury, S., Le Roy, C., Spector, T. D., & Valdes, A. M. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1863133 · Cited by 121
Diagnosis and Management of Stable Angina: A Review
Joshi, P. H., & de Lemos, J. A. (2021) · JAMA · doi:10.1001/jama.2021.1527 · Cited by 144
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Suh, S. H., & Kim, S. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0067 · Cited by 156
Zhang, X., Ritonja, J. A., Zhou, N., Chen, B. E., & Li, X. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025071 · Cited by 122
Chae, Y., Kim, D., Choi, M.-J., Cho, Y., & An, Y.-J. (2019) · Environment International · doi:10.1016/j.envint.2019.05.042 · Cited by 122
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Martín, J. E. S., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.07.010 · Cited by 206
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02427-z · Cited by 121
“Most clinical trials using therapies that lower TGs (that is, fibrates, niacin and omega-3 fatty acids, with the exception of icosapent ethyl (IPE)) have not demonstrated an add-on reduction in CV events in patients on statin therapy 4 .”
InfluentialSelf-citationElevated Lipoprotein(a) and Risk of Atrial Fibrillation
Mohammadi-Shemirani, P., Chong, M., Narula, S., Perrot, N., Conen, D., Roberts, J. D., Thériault, S., Bossé, Y., Lanktree, M. B., Pigeyre, M., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.018 · Cited by 120
Management of diabetic dyslipidemia: An update
Jialal, I., & Singh, G. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.280 · Cited by 120
Capurso, C. A., Bellanti, F., Buglio, A. L., & Vendemiale, G. (2019) · Nutrients · doi:10.3390/nu12010035 · Cited by 138
Wierzejska, R. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18178897 · Cited by 160
A Comprehensive Update on the Chylomicronemia Syndrome
Goldberg, R. B., & Chait, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.593931 · Cited by 117
Sattar, N., McMurray, J., Borén, J., Rawshani, A., Omerovic, E., Berg, N., Halminen, J., Skoglund, K., Eliasson, B., Gerstein, H. C., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063374 · Cited by 116
Self-citationZhao, Y., Zhuang, Z., Li, Y., Xiao, W., Song, Z., Huang, N., Wang, W., Dong, X., Jia, J., Clarke, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46686-x · Cited by 117
The association between triglycerides and incident cardiovascular disease: What is “optimal”?
Aberra, T., Peterson, E. D., Pagidipati, N. J., Mulder, H., Wojdyla, D. M., Philip, S., Granowitz, C., & Navar, A. M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.009 · Cited by 115
Self-citation2024 Clinical practice guidelines for Stable coronary artery disease
Барбараш, О. Л., Karpov, Y. A., Panov, A. V., Akchurin, R. S., Alekyan, B. G., Alekhin, M. N., Aronov, D. M., HARUTYUNYAN, G., Belenkov, Y. N., Boytsov, S. A., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6110 · Cited by 182
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114
Miyauchi, K., Iwata, H., Nishizaki, Y., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065520 · Cited by 114
“7 These findings indicate that a difference in dietary intake of fish remains between Japanese and Western individuals, although the intake in Japanese individuals is decreasing over time.”
InfluentialLawler, P. R., Kotrri, G., Koh, M., Goodman, S. G., Farkouh, M. E., Lee, D. S., Austin, P. C., Udell, J. A., & Ko, D. T. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz767 · Cited by 113
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use
Pocock, S., Gregson, J., Collier, T. J., Ferreira, J. P., & Stone, G. W. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae647 · Cited by 132
The Diagnosis and Treatment of Hypertriglyceridemia
Parhofer, K. G., & Laufs, U. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0825 · Cited by 110
Dietary Bioactive Fatty Acids as Modulators of Immune Function: Implications on Human Health
Kumar, N. G., Contaifer, D., Madurantakam, P. A., Carbone, S., Price, E. T., Tassell, B. W. V., Brophy, D. F., & Wijesinghe, D. S. (2019) · Nutrients · doi:10.3390/nu11122974 · Cited by 121
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Ferraro, R., Latina, J. M., Alfaddagh, A., Michos, E. D., Blaha, M. J., Jones, S. R., Sharma, G. V., Trost, J. C., Boden, W. E., Weintraub, W. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.078 · Cited by 131
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 129
Acute coronary syndromes: mechanisms, challenges, and new opportunities
Kraler, S. C., Mueller, C. E., Libby, P., & Bhatt, D. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf289 · Cited by 146
Self-citationEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“011) lower risk for MACE, respectively [104, 105].”
BackgroundMethodInfluentialGómez-Delgado, F., Katsiki, N., López‐Miranda, J., & Pérez‐Martínez, P. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1764487 · Cited by 134
Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
Duran, E. K., & Pradhan, A. D. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa296 · Cited by 109
Metherel, A. H., & Bazinet, R. P. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.101008 · Cited by 116
Triglycerides and risk of atherosclerotic cardiovascular disease: An update
Farnier, M., Zeller, M., Masson, D., & Cottin, Y. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.11.006 · Cited by 121
Dietary ω-3 polyunsaturated fatty acids are protective for myopia
Pan, M., Zhao, F., Xie, B., Wu, H., Zhang, S., Ye, C., Guan, Z., Kang, L., Zhang, Y., Zhou, X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104689118 · Cited by 111
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 119
Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases
Abdolmaleki, F., Kovanen, P. T., Mardani, R., Hayat, S. M. G., Bo, S., & Sahebkar, A. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08754-9 · Cited by 117
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials
Gregson, J., Sharples, L. D., Stone, G. W., Burman, C., Öhrn, F., & Pocock, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1034 · Cited by 115
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 106
Donia, T., & Khamis, A. A. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-14109-9 · Cited by 134
Pilecky, M., Závorka, L., Arts, M. T., & Kainz, M. J. (2021) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12747 · Cited by 120
Health Benefits, Food Applications, and Sustainability of Microalgae-Derived N-3 PUFA
Liu, Y., Ren, X., Fan, C., Wu, W., Zhang, W., & Wang, Y. (2022) · Foods · doi:10.3390/foods11131883 · Cited by 103
Nurmohamed, N. S., van Rosendael, A. R., Danad, I., Ngo‐Metzger, Q., Taub, P. R., Ray, K. K., Figtree, G. A., Bonaca, M. P., Hsia, J. A., Rodríguez, F., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae190 · Cited by 133
Self-citationOrringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
Self-citationMineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
Self-citationElshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 103
Li, Z.-H., Zhong, W.-F., Liu, S., Kraus, V. B., Zhang, Y.-J., Gao, X., Lv, Y.-B., Shen, D., Zhang, X.-R., Zhang, P.-D., et al. (2020) · BMJ · doi:10.1136/bmj.m456 · Cited by 99
Handelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 119
Inflammation and cardiovascular disease: are marine phospholipids the answer?
Lordan, R., Redfern, S., Tsoupras, A., & Zabetakis, I. (2020) · Food & Function · doi:10.1039/c9fo01742a · Cited by 101
de Bus, I., Witkamp, R., Zuilhof, H., Albada, B., & Balvers, M. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106351 · Cited by 100
Banach, M., Surma, S., Reiner, Z., Katsiki, N., Penson, P. E., Fras, Z., Sahebkar, A., Paneni, F., Rizzo, M., & Kastelein, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01684-5 · Cited by 100
Intracranial Atherosclerotic Disease
Yaghi, S. R., Prabhakaran, S., Khatri, P., & Liebeskind, D. S. (2019) · Stroke · doi:10.1161/strokeaha.118.024147 · Cited by 100
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.043 · Cited by 97
Self-citationPolygenic Hyperlipidemias and Coronary Artery Disease Risk
Ripatti, P., Rämö, J. T., Mars, N. J., Fu, Y., Lin, J., Söderlund, S., Benner, C., Surakka, I., Kiiskinen, T., Havulinna, A. S., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002725 · Cited by 104
Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97
Self-citationNutritional Challenges in Metabolic Syndrome
Hoyas, I., & Leon-Sanz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091301 · Cited by 95
Serhan, C. N., Libreros, S., & Nshimiyimana, R. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101597 · Cited by 108
de Groot, R. H. M., Emmett, R., & Meyer, B. J. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519000138 · Cited by 114
Prevention of complications from use of conventional immunosuppressants: a critical review
Ponticelli, C., & Glassock, R. J. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00602-5 · Cited by 108
Menopause symptom management in women with dyslipidemias: An EMAS clinical guide
Anagnostis, P. G., Bitzer, J., Cano, A., Ceauşu, I., Chedraui, P. A., Durmuşoğlu, F., Erkkola, R., Goulis, D. G., Hirschberg, A. L., Kiesel, L., et al. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.03.007 · Cited by 109
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health
Djuricic, I. D., & Calder, P. C. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-090208 · Cited by 121
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Predicting the effects of supplemental EPA and DHA on the omega-3 index
Walker, R. E., Jackson, K. H., Tintle, N. L., Shearer, G. C., Bernasconi, A., Masson, S., Latini, R., Heydari, B., Kwong, R. Y., Flock, M., et al. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz161 · Cited by 93
Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance
Crupi, R., & Cuzzocrea, S. (2022) · Biomolecules · doi:10.3390/biom12020242 · Cited by 107
Goldstein, L. B., Toth, P. P., Dearborn-Tomazos, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., Woo, D., & on behalf of the American Heart Association Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. C. O. P. V. D. A. S. C. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 92
EPA and DHA containing phospholipids have contrasting effects on membrane structure
Sherratt, S. C. R., Juliano, R. A., Copland, C., Bhatt, D. L., Libby, P., & Mason, R. P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100106 · Cited by 92
Self-citationHDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease
Kontush, A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.005 · Cited by 101
Pérez de Isla, L., Díaz-Díaz, J. L., Romero, M. J., Muñiz-Grijalvo, O., Mediavilla, J. D., Argüeso, R., Sánchez Muñoz-Torrero, J. F., Rubio, P., Álvarez-Baños, P., Ponte, P., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062557 · Cited by 90
Altanam, S. Y., Darwish, N., & Bakillah, A. (2025) · Diseases · doi:10.3390/diseases13090309 · Cited by 136
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Targeting immune cell recruitment in atherosclerosis
Döring, Y., van der Vorst, E. P. C., & Weber, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01023-z · Cited by 112
Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018
Li, Z., Zhu, G., Chen, G., Luo, M., Liu, X., Chen, Z., & Qian, J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01721-y · Cited by 105
Carracedo, M., Artiach, G., Arnardottir, H., & Bäck, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00767-y · Cited by 88
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.